Previous Close | 0.0800 |
Open | 0.0800 |
Bid | 0.0750 x N/A |
Ask | 0.0800 x N/A |
Day's Range | 0.0800 - 0.0800 |
52 Week Range | 0.0100 - 0.1000 |
Volume | |
Avg. Volume | 155,948 |
Market Cap | 11.609M |
Beta (5Y Monthly) | 0.12 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.1200 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the "Company") is providing this bi-weekly update on the status of the management cease trade order granted on February 29, 2024 (the "MCTO"), by its principal regulator, the Ontario Securities Commission (the "OSC"), under National Policy 12-203 - Management Cease Trade Orders ("NP 12-203"), following the Company's announcement on February 21, 2024 (the "Default Announcement"), that it was unable to file its audited annual financi
Announces it has appointed Christopher Cherry as Chief Financial Officer. Mr. Cherry, a Chartered Accountant ...
BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the "Company") is pleased to announce that it has appointed Christopher Cherry as Chief Financial Officer. Mr. Cherry, a Chartered Accountant and Certified Public Accountant, has extensive experience, having served as a CFO of many public issuers in a broad range of sectors. Mr. Cherry responsibilities will include full cycle accounting, supervision and planning, financial statement preparation, management discussion and analysis (